Midcap Value Alert: 3 Years of Subscription at the Price of 1
Here is the latest financial fact sheet of BERYL DRUGS. For more details, see the BERYL DRUGS quarterly results and BERYL DRUGS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 1.8 |
No. of shares | m | 5.07 |
1 Week | % | -3.8 |
1 Month | % | -6.3 |
1 Year | % | 133.4 |
52 week H/L | Rs | 45.0/13.1 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
BERYL DRUGS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 18 | 9 | 10 | 19 | 18 | |
Low | Rs | 6 | 4 | 3 | 5 | 8 | |
Sales per share (Unadj.) | Rs | 25.6 | 25.3 | 27.8 | 28.8 | 53.0 | |
Earnings per share (Unadj.) | Rs | 1.2 | 0.1 | 0.5 | -1.3 | 1.5 | |
Diluted earnings per share | Rs | 1.2 | 0.1 | 0.5 | -1.3 | 1.5 | |
Cash flow per share (Unadj.) | Rs | 1.8 | 1.4 | 3.0 | 0.8 | 3.1 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 14.8 | 15.0 | 15.6 | 14.4 | 15.9 | |
Adj. book value per share | Rs | 14.8 | 15.0 | 15.6 | 14.4 | 15.9 | |
Shares outstanding (eoy) | m | 5.07 | 5.07 | 5.07 | 5.07 | 5.07 | |
Price / Sales ratio | x | 0.5 | 0.2 | 0.2 | 0.4 | 0.2 | |
Avg P/E ratio | x | 10.0 | 64.9 | 14.2 | -9.4 | 8.4 | |
P/CF ratio (eoy) | x | 6.4 | 4.4 | 2.2 | 14.5 | 4.1 | |
Price / Book Value ratio | x | 0.8 | 0.4 | 0.4 | 0.9 | 0.8 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 59 | 31 | 34 | 62 | 65 | |
Total wages/salary | Rs m | 8 | 9 | 10 | 11 | 15 |
BERYL DRUGS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 130 | 128 | 141 | 146 | 269 | |
Other income | Rs m | 2 | 2 | 2 | 2 | 3 | |
Total revenues | Rs m | 132 | 130 | 143 | 148 | 272 | |
Gross profit | Rs m | 10 | 9 | 19 | 4 | 20 | |
Depreciation | Rs m | 3 | 7 | 13 | 11 | 8 | |
Interest | Rs m | 1 | 3 | 5 | 5 | 5 | |
Profit before tax | Rs m | 8 | 2 | 3 | -10 | 10 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 2 | 1 | 1 | -3 | 2 | |
Profit after tax | Rs m | 6 | 0 | 2 | -7 | 8 | |
Gross profit margin | % | 7.9 | 7.1 | 13.5 | 3.0 | 7.4 | |
Effective tax rate | % | 25.8 | 69.6 | 31.1 | 30.7 | 22.1 | |
Net profit margin | % | 4.6 | 0.4 | 1.7 | -4.5 | 2.8 |
BERYL DRUGS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 54 | 75 | 102 | 105 | 104 | |
Current liabilities | Rs m | 55 | 66 | 82 | 85 | 64 | |
Net working cap to sales | % | -1.0 | 6.9 | 13.8 | 13.6 | 14.8 | |
Current ratio | x | 1.0 | 1.1 | 1.2 | 1.2 | 1.6 | |
Inventory Days | Days | 33 | 30 | 25 | 27 | 14 | |
Debtors Days | Days | 96,803,134 | 98,381,106 | 1,176 | 1,112 | 937 | |
Net fixed assets | Rs m | 91 | 94 | 85 | 71 | 71 | |
Share capital | Rs m | 51 | 51 | 51 | 51 | 51 | |
"Free" reserves | Rs m | 24 | 25 | 28 | 22 | 30 | |
Net worth | Rs m | 75 | 76 | 79 | 73 | 81 | |
Long term debt | Rs m | 13 | 23 | 20 | 17 | 27 | |
Total assets | Rs m | 145 | 169 | 186 | 176 | 175 | |
Interest coverage | x | 6.5 | 1.5 | 1.7 | -1.1 | 3.1 | |
Debt to equity ratio | x | 0.2 | 0.3 | 0.3 | 0.2 | 0.3 | |
Sales to assets ratio | x | 0.9 | 0.8 | 0.8 | 0.8 | 1.5 | |
Return on assets | % | 5.1 | 2.2 | 3.8 | -1.1 | 7.1 | |
Return on equity | % | 7.8 | 0.6 | 3.0 | -9.0 | 9.5 | |
Return on capital | % | 10.7 | 4.8 | 8.2 | -5.5 | 13.4 | |
Exports to sales | % | 0 | 0 | 1.3 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 2 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 0 | 0 | 2 | 0 | 0 | |
Fx outflow | Rs m | 0 | 0 | 0 | 0 | 0 | |
Net fx | Rs m | 0 | 0 | 2 | 0 | 0 |
BERYL DRUGS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 33 | 2 | 3 | -5 | 25 | |
From Investments | Rs m | -50 | -16 | 3 | 5 | -13 | |
From Financial Activity | Rs m | 16 | 17 | -5 | -2 | -12 | |
Net Cashflow | Rs m | -0 | 3 | 1 | -2 | 0 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Sudhir Sethi | COMP SEC: Neha Sharma | YEAR OF INC: 1993 | BSE CODE: 524606 | FV (Rs): 10 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare BERYL DRUGS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Asian share markets made a cautious start on Monday in a week where inflation figures could make or break hopes for earlier US rate cuts.